Short answer
MYRIAD GENETICS INC (MYGN) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $206M (down 3.6% year over year) with net income of −$27M.
Q3 2025 key financials · XBRL
- Revenue
- $206M
- −3.6% YoY · −3.5% QoQ
- Net income
- −$27M
- −24.0% YoY · +91.7% QoQ
- Operating margin
- -11.3%
- Gross margin
- 69.9%
- EPS (diluted)
- −$0.29
- −16.0% YoY · +91.9% QoQ
Source: XBRL data from the MYRIAD GENETICS INC (MYGN) Q3 2025 10-Q on SEC EDGAR. USD.
MYRIAD GENETICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $205.7M, down $7.6M YoY from $213.3M
- Cost margin 69.9% vs 70.2% YoY; operating expenses 81.2% of revenue vs 78.6%
- Best category Hereditary Cancer revenue $93.0M, up $2.5M; worst Pharmacogenomics $38.7M, down $9.0M
- New $125.0M term loan; $60.2M used to repay prior ABL facility
- UnitedHealthcare GeneSight coverage changes expected to continue pressuring Pharmacogenomics revenue
Risk Factors
- New FDA oversight uncertainty after March 31, 2025 court vacatur of the LDT final rule
- Senior leadership transition risk following CEO, COO, CCO, and CFO changes between April and August 2025
- Medicaid and ACA marketplace enrollment reductions expected under the One Big Beautiful Bill Act
- Strategic plan execution risk from expanded CCC investment and planned MRD testing-market entry
- Financing risk from July 31, 2025 secured credit agreement and related pledge arrangements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MYRIAD GENETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.